AMR Market Expected to Reach USD 21.6 B by 2031 as Phage Therapy...

AMR Market Expected to Reach USD 21.6 B by 2031 as Phage Therapy and AI Combat the "Silent Pandemic"

Posté 2025-04-18 11:10:04

[Hyderabad, April 18th, 2025]– The Anti-Microbial Resistance Market, valued at 9.4 billion in 2023, will grow at 10.9% to 10.921.6 billion by 2031, as superbugs outpace traditional antibiotics, reports ClearView Market Insights.

Request Sample @ https://clearviewmarketinsights.com/report-details/global-anti-microbial-resistance-market/

2024 Turning Points

Bacteriophage Renaissance

The first FDA-approved phage cocktail achieves 100% MRSA clearance.
CRISPR-engineered phages directly target resistance genes.

AI Reshapes Drug Discovery

Exscientia's XAI-101 shows ten times the potency against gram-negative bacteria.
3 new AMR targets identified via machine learning.

Diagnostics Revolution

45-minute resistance detection slashes inappropriate antibiotic use.
Real-time sequencing tracks outbreaks in hospitals.

Regional Responses

North America (45%): Leading in novel drug incentives.
Europe (XX%): Phage therapy approvals and stewardship.
Asia (XX%): Scaling rapid diagnostics to curb misuse.

Executive Insights
"We're fighting evolution with evolution – using phages and AI to outsmart superbugs."
– David Huang, CEO, Adaptive Phage Therapeutics

Roadmap to 2031

2025: 50% of US hospitals adopt rapid AMR diagnostics.
2027: Phage-antibiotic combos standard for chronic infections.
2030: AI-designed drugs target 90% of known resistance mechanisms.

For more insights, visit https://clearviewmarketinsights.com/report-store

About Clearview Market Insights:

Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.

Media contact:

Bhavani K

Marketing and Sales Head

ClearView Market Insights

Mail: sales@clearviewmarketinsights.com

Phone: +1 917-993-7369